This page brings together the European Medicines Agency's (EMA) latest information on diabetes. It lists:
Segluromet is a medicine used to treat adults with type 2 diabetes together with diet and exercise. Segluromet can be used alone or together with other diabetes medicines when glucose (sugar) levels...
This is a summary of the European public assessment report (EPAR) for Lyxumia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
This is a summary of the European public assessment report (EPAR) for Tesavel. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
Ogluo is a medicine for treating severe hypoglycaemia (very low levels of glucose in the blood) in patients with diabetes who are at least 2 years old. Hypoglycaemia can occur when diabetes medicines...
This is a summary of the European public assessment report (EPAR) for Efficib. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
Four new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended granting a marketing authorisation for Sotyktu (deucravacitinib) for the treatment of moderate to severe plaque psoriasis in adults, a skin disease...
Five new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2022 meeting. The CHMP recommended granting a conditional marketing authorisation for the advanced therapy...
Nine new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its May 2022 meeting. A recommendation for marketing authorisation was adopted for Cevenfacta (eptacog beta (activated))...
EMA’s human medicines committee (CHMP) has given a recommendation for two diabetes mellitus treatments, Actrapid and Insulatard, for use outside the European Union (EU). EMA is committed to supporting global regulatory capacity building and...
EMA’s human medicines committee (CHMP) recommended thirteen medicines for approval at its February 2022 meeting. The CHMP gave a positive opinion for Kimmtrak * (tebentafusp) for the treatment of uveal melanoma, a type of eye cancer. Kimmtrak was...
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its January 2022 meeting. The antiviral Paxlovid (PF-07321332 / ritonavir) received a positive opinion from the Committee for a conditional marketing authorisation...